Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III).

MLA

Sferra, Thomas J., et al. “Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides Difficile Infection (MODIFY III).” Journal of the Pediatric Infectious Diseases Society, vol. 12, no. 6, June 2023, pp. 334–41. EBSCOhost, https://doi.org/10.1093/jpids/piad031.

APA

Sferra, T. J., Merta, T., Neely, M., Oliveira, C. M. de, Lassaletta, A., Guasch, C. F., Dorr, M. B., Winchell, G., Su, F.-H., Perko, S., Fernsler, D., Waskin, H., & Holden, S. R. (2023). Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III). Journal of the Pediatric Infectious Diseases Society, 12(6), 334–341. https://doi.org/10.1093/jpids/piad031

Chicago

Sferra, Thomas J, Tomas Merta, Michael Neely, Claudia Murta de Oliveira, Alvaro Lassaletta, Claudia Fortuny Guasch, Mary Beth Dorr, et al. 2023. “Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides Difficile Infection (MODIFY III).” Journal of the Pediatric Infectious Diseases Society 12 (6): 334–41. doi:10.1093/jpids/piad031.